Ticker

Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 925,918 shares of the company's stock after buying an additional 430,014 shares during

Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer significant upside, despite NMIBC's competitive landscape and lower CR rates. IV Choline Chloride, targeting severe choline deficiency in parenteral nutrition patients, could generate substantial revenue if approved, with…

Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average

Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointment of Tara Bunch, former Senior Vice President and Global Head of Operations at Airbnb, to its Board of Directors. Bunch brings more than three decades of experience scaling global technology organizations, leading complex operations, strengthening customer experience, and advancing digital transformation across…